Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ASP 7517

Next Previous
Search
Drug Profile

ASP 7517

Alternative Names: ASP-7517

Latest Information Update: 07 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; RIKEN
  • Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Cell replacements; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 21 Jun 2024 Astellas Pharma completes a phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Combination therapy, Monotherapy, Second-line therapy or greater) in USA (IV) (NCT04837196)
  • 01 Jun 2023 Astellas Pharma completes a phase I/II trial in Acute myeloid leukaemia (Second-line therapy or greater) in Japan and USA (IV) (NCT04079296)
  • 01 Jun 2023 Astellas Pharma completes a phase I/II trial in Myelodysplastic syndromes (Second-line therpy or greater)in Japan and USA (IV) (NCT04079296)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top